Unum Therapeutics, which is developing antibody-coupled T cell immunotherapies for cancers, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Cambridge, MA-based company was founded in 2014 and plans to list on the Nasdaq under the symbol UNUM. Unum Therapeutics filed confidentially on November 3, 2017. Morgan Stanley and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
